Here are the top health stories for the day:
Supreme Court hearing on NEET PG 2023 postponed to continue on Monday
The Supreme Court has deferred the hearing for the petitions seeking NEET PG 2023 postponement.
A bench comprising Justices S Ravindra Bhat and Dipankar Datta heard the appeals and adjourned the matter till Monday next week, 27th February.
Supreme Court Hearing: The hearing started with Sr. Adv. Gopal Sankaranarayanan appearing on behalf petitioners seeking deferment of the PG medical entrance test. He said, “There are 13 petitioners before your lordships…But about 45,000 other would be affected.”
For more details, check out the link given below:
SC Hearing On NEET PG 2023 Postponed To Continue On Monday, Here Is What Happened Today
NEET PG 2023 postponement: NMC releases speaking order against representations
The National Medical Commission (NMC) has issued its speaking order disposing off of all pleas for NEET PG 2023 postponement.
The order is in response to the several representations submitted by the aspirants pushing for an exam date extension to reduce the gap of around five months between the date of the NEET PG 2023 exam and the date of MBBS internship completion.
For more details, check out the link given below:
NEET PG 2023 Postponement: NMC Releases Speaking Order Against Representations
Government Dental College Srinagar gets permission from Health ministry for increasing MDS seats
Bringing goods news to the Postgraduate dental aspirants in Jammu and Kashmir, the Union Ministry of Health and Family Welfare (MoHFW) has given its permission for increasing the intake capacity of MDS course in four specialties at the Government Dental College & Hospital (GDC&H).
Intake capacity has been increased from 3 to 4 in specialties including Oral & Maxillofacial Surgery, Conservative Dentistry and Endodontics, Periodontology, Prosthodontics and Crown & Bridge.
For more details, check out the link given below:
Health Ministry Grants Permission For Increasing MDS Seats At Government Dental College Srinagar
Sun Pharma gets CDSCO panel nod to manufacture, market antidiabetic FDC drug
In a significant development, pharmaceutical major, Sun Pharma has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market the popular anti-diabetic fixed dose combination (FDC) drug comprising Dapagliflozin Propanediol Monohydrate, Sitagliptin, and Metformin Hydrochloride.
This came after the company presented the committee with the clinical report (CT) of the FDC Dapagliflozin Propanediol plus Sitagliptin plus Metformin Hydrochloride tablets.
For more details, check out the link given below:
Sun Pharma Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug
